01 1Cipla
01 1RIVAROXABAN
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2021-04-21
Pay. Date : 2021-04-16
DMF Number : 35649
Submission : 2021-04-05
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RIVAROXABAN, with a corresponding US DMF Number 35649.
Remarkably, this DMF maintains an Active status since its submission on April 05, 2021, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 21, 2021, and payment made on April 16, 2021, indicating their dedication to facilitating drug approvals, Categorized as Type II
